Vivera Pharmaceuticals is an innovative, science-driven pharmaceutical company located in Southern California. The Company has global exclusivity to license the patented and patent-pending TABMELT® sublingual drug delivery system for pharmaceutical use and holds its own issued patents on ZICOH®, a smart dose-controlled medical device. It also has patents pending on its telemedicine station, MD ZONE. With multiple divisions, including its pharmaceutical, neurosciences, medical technology, biosciences, and advanced diagnostics divisions, Vivera Pharmaceuticals is vertically integrated with patented technology, manufacturing capabilities, and distribution for its products.
Vivera is committed to the continued research and development of innovative therapies across the spectrum. We believe that now is the time to combat some of the most unprecedented issues affecting patients and their caregivers by redefining the landscape with safe, yet effective, non-addictive treatment alternatives for pain management and the latest in medical device technologies. From strength in vision to channeled realization, we believe the path forward begins with the requirement to put patients first. Our foremost mission is to enhance the lives of millions of neighbors, families, and the leaders of tomorrow, through ceaseless development of life-changing new therapies.
Vivera is dedicated to making a positive difference for vulnerable communities across the world. Through our non-profit organization, Vivera Cares, we are helping underserved communities, like Tribal Nations and frontline workers, access the resources they need to keep their communities safe and healthy. With our continued support, we can envision a brighter future for our communities, patients, and providers.
Vivera Executes Letter of Intent to Enter a Cooperative Research and Development Agreement with the NINDS of NIH to Assess Therapeutic Agents for Potential Treatments
NEWPORT BEACH, Calif. — Vivera Pharmaceuticals, Inc. is pleased to announce that it has received a Notice of Allowance for U.S. Patent Application No. 17/066,985
NEWPORT BEACH, Calif.— As large corporations are being held responsible for fueling the opioid crisis, an estimated $32 billion in settlements are being allocated to
NEWPORT BEACH, Calif.— Vivera Pharmaceuticals, Inc. today announced the appointment of leading corporate law firm, Byrd Campbell, P.A., to represent the Company in its defamation
Vivera Pharmaceuticals is highly discouraged to read the latest FDA safety communication that erroneously lists Vivera Pharmaceuticals as a brand of LuSys Laboratories or as
NEWPORT BEACH, Calif. Vivera Pharmaceuticals announced today, the appointment of Donald D’Ambrosio as the Company’s Chief Financial Officer (CFO). With over four decades of experience serving in executive and officer
Telemedicine involves the use of electronic communications and software like computers, video, phones, or messaging to provide clinical services to patients virtually. Telemedicine can effectively
Poisoning can happen to people of all ages, but incidences disproportionately affect children younger than six years old, with peak poison frequency occurring in one and two-year-olds.
Opioids are medications prescribed by doctors to treat pain. They are called opioids because they attach to the opioid receptors in the brain and throughout
The United States has been fighting an opioid epidemic since the late 1990s. Unfortunately, much of our progress has backtracked during the COVID-19 pandemic. Not
Opioids are a drug class used to reduce pain. They work by binding to opioid receptors throughout the body to block pain messages sent to the brain
Stress is a normal part of life. It’s how the body and brain respond to external stimuli. To a certain extent, stress is beneficial. It
Innovation is the lifeblood of Vivera. With six divisions, each focused on a specific crisis response, Vivera’s vertically integrated structure has created an agile and responsive model.
Vivera is working to change the future of drug delivery, medical device, and medical technologies at home and across the globe with its extensive intellectual property portfolio.
English
Arabic
Armenian
Chinese (Simplified)
Chinese (Traditional)
Czech
Dutch
Tagalog
French
Frisian
German
Irish
Italian
Korean
Farsi
Polish
Portuguese
Romanian
Russian
Spanish
Swedish
Ukrainian
Vietnamese